Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis.

Abstract

Uveitis is a major cause of ocular morbidity, potentially leading to significant visual impairment. The recent adoption of alternative drug delivery options has led to the development of new sustained-delivery corticosteroid systems, able to manage successfully chronic noninfectious posterior uveitis. The treatment goal is to target the site of inflammation with low dose of corticosteroids, delivered over an extended period of time, to minimize the cumulative damage resulting from repeated recurrences, reducing both injections frequency and ocular side effects. This article will review the pharmacology and preliminary clinical data of the 0.18 mg fluocinolone acetonide intravitreal implant (YUTIQ™), to show its efficacy and safety in the treatment of noninfectious posterior uveitis.

• Authors: Ilaria Testi, Carlos Pavesio
• Journal: Therapeutic delivery (Ther Deliv) Vol. 10 Issue 10 Pg. 621-625 (10 2019) ISSN: 2041-6008 [Electronic] England
• PMID: 31663454 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Delayed-Action Preparations
• Drug Implants
• Glucocorticoids
• Fluocinolone Acetonide

Topics

• Chronic Disease (drug therapy)
• Clinical Trials, Phase III as Topic
• Delayed-Action Preparations (administration & dosage, pharmacokinetics)
• Dose-Response Relationship, Drug
• Drug Implants (administration & dosage)
• Drug Liberation
• Fluocinolone Acetonide (administration & dosage, pharmacokinetics)
• Glucocorticoids (administration & dosage, pharmacokinetics)
• Humans
• Randomized Controlled Trials as Topic
• Treatment Outcome
• Uveitis, Posterior (drug therapy)